Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Epstein-Barr virus (EBV) establishes lifelong infections and is associated with several cancers.
• Cytotoxic T lymphocytes (CTLs) play a crucial role in controlling EBV infection by targeting viral antigens.
• Current CTL-based therapies are effective against EBV-positive immunoblastic lymphoma but need to target subdominant antigens for other EBV-associated malignancies.

Purpose of the Study:

• To identify novel CTL target epitopes within the EBV latent membrane protein 2 (LMP2) that are relevant for treating EBV-positive cancers.
• To investigate the conservation of these LMP2 epitopes across different EBV strains and their restriction by HLA alleles prevalent in high-risk populations.

Main Methods:

• Analysis of EBV-infected healthy carriers (Caucasian and Chinese) to identify CTL target epitopes.
• Epitope mapping within the LMP2 protein.
• Assessment of HLA allele restriction, particularly common alleles in Southern China (HLA-A2, A11, A24, B40).
• Investigation of HLA subtype polymorphism and EBV sequence conservation.

Main Results:

• Five CTL target epitopes within LMP2 were identified, restricted by HLA alleles common in Southern Chinese populations.
• LMP2 epitope sequences demonstrated significant antigenic conservation across diverse EBV isolates, including those from nasopharyngeal carcinoma and Hodgkin's disease.
• HLA-A2 subtype polymorphism was analyzed in the context of epitope presentation.

Conclusions:

• Nasopharyngeal carcinoma and Hodgkin's disease are predicted to express LMP2 proteins containing conserved CTL target epitopes.
• These epitopes are restricted by common HLA alleles, suggesting their potential for therapeutic targeting.
• Boosting CTL responses against these conserved LMP2 epitopes could form the basis for novel CTL-based immunotherapies for these malignancies.